UX007-CL201: An Open-Label Phase 2 Study to Assess Safety and Clinical Effects of UX007 in Subjects with Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)

Project: Research project

Project Details

StatusFinished
Effective start/end date10/17/1310/17/16

Funding

  • Ultragenyx Pharmaceutical Inc. (UX007-CL201)